SUBSEQUENT EVENTS	9 Months Ended
Jun. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 6 – SUBSEQUENT EVENTS Issuance of Loans Payable Subsequent to June 30, 2021, the Company received an aggregate of $232,500 related to the issuance of 11 notes payable to various noteholders, including an aggregate of $30,000 as a result of a note payable issued to the Company’s Chief Executive Officer, a related party. The notes are unsecured, bear interest at 1.5% per annum, and mature on September 30, 2021. To date, the Company has made principal and accrued interest payment of $65,000 and $14,191, respectively. As of the date of this report, the original due date of such notes has not been extended and are in default.

SUBSEQUENT EVENTS

9 Months Ended

Jun. 30, 2021

NOTE 6 – SUBSEQUENT EVENTS

Issuance of Loans Payable

Subsequent to June 30, 2021, the Company received an aggregate of $232,500 related to the issuance of 11 notes payable to various noteholders, including an aggregate of $30,000 as a result of a note payable issued to the Company’s Chief Executive Officer, a related party. The notes are unsecured, bear interest at 1.5% per annum, and mature on September 30, 2021. To date, the Company has made principal and accrued interest payment of $65,000 and $14,191, respectively. As of the date of this report, the original due date of such notes has not been extended and are in default.

PEAK PHARMACEUTICALS, INC. 10-Q